MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • SARS-CoV-2 Vaccine
    • Retinal Degeneration
    • Publications
  • News & Media
  • Contact Us
MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • SARS-CoV-2 Vaccine
    • Retinal Degeneration
    • Publications
  • News & Media
  • Contact Us
  •  
  • June 2016

AiVita Biomedical Receives FDA Approval for Phase II Ovarian Cancer Treatment

AIVITA Biomedical is a biotechnology company developing personalized vaccines that target COVID-19 and the seed of all cancers using our autologous cell platform. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development in cancer, infectious disease and other fields.

Recent News

  • AIVITA Biomedical Completes Phase 1 Study of Personalized COVID-19 Vaccine Candidate, AV-COVID-19
  • AIVITA Biomedical Closes $25 Million Financing Round
  • AIVITA Biomedical’s Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival
  • AIVITA Biomedical Completes Treatment of Patients in Phase 2 Clinical Trial of Glioblastoma Immunotherapy
  • AIVITA Biomedical Publishes Review of GM-CSF History and Rationale as Vaccine Adjuvant in Melanoma Management

Site Navigation

  • About Us
  • Programs
  • News & Media
  • Contact Us
Copyright © 2020 | AIVITA Biomedical, Inc.